2007
Risk of Second Cancer in Nongastric Marginal Zone B-Cell Lymphomas of Mucosa-Associated Lymphoid Tissue: A Population-Based Study from Northern Italy
Arcaini L, Burcheri S, Rossi A, Pascutto C, Passamonti F, Brusamolino E, Paulli M, Orlandi E, Buelli M, Viero P, Lucioni M, Montanari F, Merli M, Cortelazzo S, Lazzarino M. Risk of Second Cancer in Nongastric Marginal Zone B-Cell Lymphomas of Mucosa-Associated Lymphoid Tissue: A Population-Based Study from Northern Italy. Clinical Cancer Research 2007, 13: 182-186. PMID: 17200353, DOI: 10.1158/1078-0432.ccr-06-0703.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overFemaleGastric MucosaHumansItalyLymphoma, B-CellLymphoma, B-Cell, Marginal ZoneMaleMiddle AgedNeoplasms, Second PrimaryRiskTime FactorsTreatment OutcomeConceptsStandardized incidence ratiosMarginal zone B-cell lymphomaIncidence ratiosSecond cancersB-cell lymphomaLymphoid tissueGeneral populationSolid tumorsSkin cancerMucosa associated lymphoid tissueSex-specific incidence ratesSite of cancerNonmelanoma skin cancerMarginal zone lymphomaSitu skin cancersNongastric MALT lymphomasExtranodal sitesAdditional malignanciesPrevious malignancyCancer RegistryComparison of risksSecond tumorMALT lymphomaIncidence rateHematologic diseases
2006
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT
Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, Brusamolino E, Molteni A, Pulsoni A, Cox M, Orsucci L, Fabbri A, Frezzato M, Voso M, Zaja F, Montanari F, Merli M, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Annals Of Oncology 2006, 18: 346-350. PMID: 17071937, DOI: 10.1093/annonc/mdl388.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, ViralBiomarkersFemaleGastric MucosaHepacivirusHepatitis CHumansLymphoma, B-Cell, Marginal ZoneMaleMiddle AgedPrevalenceRetrospective StudiesSurvival RateConceptsHCV-positive patientsMarginal zone B-cell lymphomaHCV-negative patientsEvent-free survivalHCV infectionMarginal zone lymphomaB-cell lymphomaOverall survivalHigh prevalenceMost HCV-positive patientsHepatitis C virus infectionC virus infectionBone marrow involvementOverall response rateMALT sitesHCV serostatusAdvanced diseasePresenting featuresHCV serologyMarrow involvementOrgan involvementPoor OSAntiviral treatmentIndolent courseHistological diagnosisNongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination
Arcaini L, Burcheri S, Rossi A, Passamonti F, Paulli M, Boveri E, Brusamolino E, Orlandi E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F, Montanari F, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Nongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination. The Oncologist 2006, 11: 285-291. PMID: 16549813, DOI: 10.1634/theoncologist.11-3-285.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnthracyclinesAntibodies, MonoclonalAntigens, CD20Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBone Marrow NeoplasmsChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansItalyLymphatic MetastasisLymphoma, B-Cell, Marginal ZoneMaleMiddle AgedMultivariate AnalysisPrognosisRadiotherapy, AdjuvantRetrospective StudiesConceptsBone marrow involvementMarrow involvementNodal involvementClinical featuresSurvival timeBone marrowMedian event-free survival timeB-cell MALT lymphomaMedian overall survival timeDisease disseminationEvent-free survival timeB-cell mucosaStage IV diseaseOverall survival timeLymphoid tissue lymphomaMarginal zone lymphomaLonger EFSNodal diseaseShorter OSOS timeTissue lymphomaWaldeyer's ringPoor outcomePrognostic significancePrognostic value